Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Sunday, Wall Street Zen reports.
KMTS has been the topic of a number of other research reports. Evercore started coverage on shares of Kestra Medical Technologies in a report on Tuesday, October 20th. They issued an “outperform” rating and a $34.00 target price on the stock. Piper Sandler reiterated an “overweight” rating on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Royal Bank Of Canada set a $30.00 target price on Kestra Medical Technologies in a research note on Tuesday, September 15th. Oppenheimer began coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating on the stock. Finally, JPMorgan Chase & Co. began coverage on Kestra Medical Technologies in a research report on Monday, August 10th. They set an “overweight” rating and a $30.00 price target for the company. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Kestra Medical Technologies presently has an average rating of “Moderate Buy” and an average price target of $29.00.
Read Our Latest Stock Analysis on Kestra Medical Technologies
Kestra Medical Technologies Stock Performance
NASDAQ KMTS opened at $30.12 on Friday. The company has a market cap of $1.79 billion, a P/E ratio of -11.28 and a beta of 0.45. The company has a fifty day simple moving average of $27.05 and a 200 day simple moving average of $24.02. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.33. Kestra Medical Technologies has a 12-month low of $17.34 and a 12-month high of $31.91.
Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) last released its quarterly earnings data on Monday, September 14th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.14). Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. The business had revenue of $30.97 million for the quarter. Sell-side analysts predict that Kestra Medical Technologies will post -2.45 earnings per share for the current fiscal year.
Insider Activity
In related news, insider Brian Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction that occurred on Tuesday, October 20th. The shares were sold at an average price of $29.56, for a total value of $443,400.00. Following the sale, the insider owned 445,215 shares of the company’s stock, valued at approximately $13,160,555.40. The trade was a 3.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Traci S. Umberger sold 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 21st. The shares were sold at an average price of $27.18, for a total value of $2,718,000.00. Following the completion of the transaction, the insider owned 195,825 shares in the company, valued at approximately $5,322,523.50. The trade was a 33.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 266,456 shares of company stock worth $7,585,946. 5.30% of the stock is owned by insiders.
Institutional Trading of Kestra Medical Technologies
Large investors have recently bought and sold shares of the company. Sei Investments Co. lifted its position in shares of Kestra Medical Technologies by 22.6% during the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock valued at $4,726,000 after buying an additional 43,753 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in Kestra Medical Technologies by 6.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock valued at $1,844,000 after acquiring an additional 5,731 shares during the period. Bank of New York Mellon Corp raised its stake in Kestra Medical Technologies by 47.2% in the 1st quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock valued at $1,397,000 after acquiring an additional 22,471 shares during the period. Corient Private Wealth LP lifted its holdings in Kestra Medical Technologies by 284.2% during the second quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock valued at $1,542,000 after purchasing an additional 44,839 shares during the last quarter. Finally, Spartan Wealth Advisory Services LLC purchased a new stake in Kestra Medical Technologies during the first quarter valued at about $603,000.
Kestra Medical Technologies Company Profile
Kestra Medical Technologies is a medical technology company focused on wearable solutions for people at risk of sudden cardiac arrest. Its products combine cardiac monitoring, treatment technology and digital services intended to support patients and their care teams.
The company’s flagship product, the ASSURE wearable cardioverter defibrillator, continuously monitors a patient’s heart rhythm and can deliver a treatment shock if it detects a life-threatening arrhythmia. The system also provides alerts and supports remote sharing of patient data with clinicians.
Based in Kirkland, Washington, Kestra serves the U.S.
Further Reading
- Five stocks we like better than Kestra Medical Technologies
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Kestra Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kestra Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
